AKT kinase pathway: A leading target in cancer research

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Kumar, Ambuj ^a   Rajendran, Vidya ^a   Sethumadhavan, Rao ^a   Purohit, Rituraj ^a  

^a VIT UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; MICRORNA 21; MICRORNA 22; MICRORNA 26A; PERIFOSINE; PROTEIN KINASE B; TEMOZOLOMIDE; TEMSIROLIMUS; TRANSCRIPTION FACTOR FKHRL1; TRICIRIBINE; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; MICRORNA; MIRN21 MICRORNA, HUMAN; NEW DRUG; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE INHIBITOR; PTEN PROTEIN, HUMAN; RNA; TUMOR PROTEIN;

3' UNTRANSLATED REGION; APOPTOSIS; CANCER CELL; CANCER CONTROL; CANCER GROWTH; CANCER RESEARCH; CELL CYCLE ARREST; CELL PROLIFERATION; COLON CANCER; DNA METHYLATION; DRUG DESIGN; DRUG TARGETING; GENE ACTIVITY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GLIOBLASTOMA; GLIOMA CELL; HISTONE MODIFICATION; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LEUKEMIA CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA CELL; MOLECULAR DYNAMICS; PANCREAS CANCER; PROMOTER REGION; PROSTATE CANCER; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA; WALDENSTROEM MACROGLOBULINEMIA; BIOLOGY; BIOSYNTHESIS; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE SILENCING; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; COMPUTATIONAL BIOLOGY; DOXORUBICIN; DRUG DESIGN; DRUGS, INVESTIGATIONAL; FORKHEAD TRANSCRIPTION FACTORS; GENE SILENCING; HUMANS; MICRORNAS; MOLECULAR DYNAMICS SIMULATION; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA, NEOPLASM; SIGNAL TRANSDUCTION;

EID: 84890095118     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/756134     Document Type: Review

References (74)

1. Kumar A., Purohit R., Cancer associated E17K mutation causes rapid conformational drift in AKT1 Pleckstrin Homology (PH) Domain. PLoS ONE 2013 8 5 e64364
2. Edbauer D., Cheng D., Batterton M. N., Wang C.-F., Duong D. M., Yaffe M. B., Peng J., Sheng M., Identification and characterization of neuronal mitogen-activated protein kinase substrates using a specific phosphomotif antibody. Molecular & Cellular Proteomics 2009 8 4 681 695 2-s2.0-66149157346 10.1074/mcp.M800233-MCP200
3. Hennessy B. T., Smith D. L., Ram P. T., Lu Y., Mills G. B., Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Reviews Drug Discovery 2005 4 12 988 1004 2-s2.0-32044466838 10.1038/nrd1902
4. Ayala G., Thompson T., Yang G., Frolov A., Li R., Scardino P., Ohori M., Wheeler T., Harper W., High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clinical Cancer Research 2004 10 19 6572 6578 2-s2.0-5144228549 10.1158/1078-0432.CCR-04-0477 (Pubitemid 39346553)
5. Majumder P. K., Sellers W. R., Akt-regulated pathways in prostate cancer. Oncogene 2005 24 50 7465 7474 2-s2.0-27844506524 10.1038/sj.onc.1209096 (Pubitemid 41637986)
6. David O., Jett J., LeBeau H., Dy G., Hughes J., Friedman M., Brody A. R., Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clinical Cancer Research 2004 10 20 6865 6871 2-s2.0-6044230919 10.1158/1078-0432.CCR-04-0174 (Pubitemid 39383035)
7. Dhawan P., Singh A. B., Ellis D. L., Richmond A., Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor- B and tumor progression. Cancer Research 2002 62 24 7335 7342 2-s2.0-0037115394 (Pubitemid 36025257)
8. Liu L.-X., Liu Z.-H., Jiang H.-C., Qi S.-Y., Zhang W.-H., Zhu A.-L., Wang X.-Q., Wu M., Overexpression of Akt-1 gene in human hepatocellular carcinoma. Chinese Journal of Cancer Research 2002 14 3 161 164 2-s2.0-0036743543
9. Chua B. T., Gallego-Ortega D., de Molina A. R., Ullrich A., Lacal J. C., Downward J., Regulation of Akt(ser473) phosphorylation by Choline kinase in breast carcinoma cells. Molecular Cancer 2009 8, article 131 2-s2.0-74549133414 10.1186/1476-4598-8-131
10. Altomare D. A., Testa J. R., Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005 24 50 7455 7464 2-s2.0-27844445642 10.1038/sj.onc.1209085 (Pubitemid 41637985)
11. Vega A., Torres J., Torres M., Cameselle-Teijeiro J., Macia M., Carracedo Á., Pulido R., A novel loss-of-function mutation (N48K) in the PTEN gene in a Spanish patient with Cowden disease. Journal of Investigative Dermatology 2003 121 6 1356 1359 2-s2.0-0346993781 10.1111/j.1523-1747.2003.12638.x (Pubitemid 38005485)
12. Wu X., Senechal K., Neshat M. S., Whang Y. E., Sawyers C. L., The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proceedings of the National Academy of Sciences of the United States of America 1998 95 26 15587 15591 2-s2.0-0032431032 10.1073/pnas.95.26.15587 (Pubitemid 29018743)
13. Abel T. W., Baker S. J., Fraser M. M., Tihan T., Nelson J. S., Yachnis A. T., Bouffard J.-P., Mena H., Burger P. C., Eberhart C. G., Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway. Journal of Neuropathology and Experimental Neurology 2005 64 4 341 349 2-s2.0-20144387454 (Pubitemid 40489561)
14. Fresno Vara J. Á., Casado E., de Castro J., Cejas P., Belda-Iniesta C., González-Barón M., P13K/Akt signalling pathway and cancer. Cancer Treatment Reviews 2004 30 2 193 204 2-s2.0-1642617693 10.1016/j.ctrv.2003.07.007 (Pubitemid 38418057)
15. Madrid L. V., Wang C.-Y., Guttridge D. C., Schottelius A. J. G., Baldwin A. S. Jr., Mayo M. W., Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF- B. Molecular and Cellular Biology 2000 20 5 1626 1638 2-s2.0-0033961280 10.1128/MCB.20.5.1626- 1638.2000 (Pubitemid 30100182)
16. Carnero A., Blanco-Aparicio C., Renner O., Link W., Leal J. F. M., The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Current Cancer Drug Targets 2008 8 3 187 198 2-s2.0-43749120732 10.2174/ 156800908784293659 (Pubitemid 351688437)
17. He W. W., Sciavolino P. J., Wing J., Augustus M., Hudson P., Meissner P. S., Curtis R. T., Shell B. K., Bostwick D. G., Tindall D. J., Gelmann E. P., Abate-Shen C., Carter K. C., A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997 43 1 69 77 2-s2.0-0031194107 10.1006/geno.1997. 4715 (Pubitemid 27310524)
18. Shin I., Yakes F. M., Rojo F., Shin N.-Y., Bakin A. V., Baselga J., Arteaga C. L., PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nature Medicine 2002 8 10 1145 1152 2-s2.0-0036799377 10.1038/nm759 (Pubitemid 35175970)
19. Xiang T., Jia Y., Sherris D., Li S., Wang H., Lu D., Yang Q., Targeting the Akt/mTOR pathway in Brca1-deficient cancers. Oncogene 2011 30 21 2443 2450 2-s2.0-79957585507 10.1038/onc.2010.603
20. Kandel E. S., Skeen J., Majewski N., Di Cristofano A., Pandolfi P. P., Feliciano C. S., Gartel A., Hay N., Activation of Akt/protein kinase B overcomes a G2/M cell cycle checkpoint induced by DNA damage. Molecular and Cellular Biology 2002 22 22 7831 7841 2-s2.0-0036841293 10.1128/MCB.22.22.7831-7841.2002 (Pubitemid 35217294)
21. Didiano D., Hobert O., Molecular architecture of a miRNA-regulated 3′ UTR. RNA 2008 14 7 1297 1317 2-s2.0-45749154794 10.1261/rna.1082708 (Pubitemid 351872188)
22. Tan Y., Zhang B., Wu T., Skogerbø G., Zhu X., Guo X., He S., Chen R., Transcriptional inhibiton of Hoxd4 expression by miRNA-10a in human breast cancer cells. BMC Molecular Biology 2009 10, article 12 2-s2.0-65549158866 10.1186/1471-2199-10-12
23. Hawkins P. G., Morris K. V., RNA and transcriptional modulation of gene expression. Cell Cycle 2008 7 5 602 607 2-s2.0-41849131453 (Pubitemid 351498998)
24. Poliseno L., Salmena L., Zhang J., Carver B., Haveman W. J., Pandolfi P. P., A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010 465 7301 1033 1038 2-s2.0-77953957633 10.1038/nature09144
25. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S. T., Patel T., MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007 133 2 647 658 2-s2.0-34547524771 10.1053/j.gastro.2007.05.022 (Pubitemid 47187346)
26. Huse J. T., Brennan C., Hambardzumyan D., Wee B., Pena J., Rouhanifard S. H., Sohn-Lee C., Le Sage C., Agami R., Tuschl T., Holland E. C., The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes and Development 2009 23 11 1327 1337 2-s2.0-66149173789 10.1101/gad.1777409
27. Bar N., Dikstein R., miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics. PloS ONE 2010 5 5 e10859 2-s2.0-77956292550 10.1371/journal.pone.0010859
28. Pezzolesi M. G., Platzer P., Waite K. A., Eng C., Differential expression of PTEN-targeting MicroRNAs miR-19a and miR-21 in Cowden syndrome. American Journal of Human Genetics 2008 82 5 1141 1149 2-s2.0-42949164608 10.1016/j.ajhg.2008.04.005 (Pubitemid 351615147)
29. Liang Z., Li Y., Huang K., Wagar N., Shim H., Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharmaceutical Research 2011 28 12 3091 3100 2-s2.0-83555173262 10.1007/s11095-011-0570-y
30. Horiguchi K., Sakamoto K., Koinuma D., Semba K., Inoue A., Inoue S., Fujii H., Yamaguchi A., Miyazawa K., Miyazono K., Saitoh M., TGF- β drives epithelial-mesenchymal transition through δ EF1-mediated downregulation of ESRP. Oncogene 2011 2-s2.0-80055016488 10.1038/onc.2011.493
31. Astle M. V., Hannan K. M., Ng P. Y., Lee R. S., George A. J., Hsu A. K., Haupt Y., Hannan R. D., Pearson R. B., AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene 2012 31 15 1949 1962 2-s2.0-84859754266 10.1038/onc.2011.394
32. Orr B., Riddick A. C. P., Stewart G. D., Anderson R. A., Franco O. E., Hayward S. W., Thomson A. A., Identification of stromally expressed molecules in the prostate by tag-profiling of cancer-associated fibroblasts, normal fibroblasts and fetal prostate. Oncogene 2012 31 9 1130 1142 2-s2.0-84857793831 10.1038/onc.2011.312
33. Lee J., Li L., Gretz N., Gebert J., Dihlmann S., Absent in melanoma 2 (AIM2) is an important mediator of interferon-dependent and -independent HLA-DRA and HLA-DRB gene expression in colorectal cancers. Oncogene 2012 31 10 1242 1253 2-s2.0-84858008055 10.1038/onc.2011.320
34. Joha S., Nugues A.-L., Hétuin D., Berthon C., Dezitter X., Dauphin V., Mahon F.-X., Roche-Lestienne C., Preudhomme C., Quesnel B., Idziorek T., GILZ inhibits the mTORC2/AKT pathway in BCR-ABL+ cells. Oncogene 2012 31 11 1419 1430 2-s2.0-84858336307 10.1038/onc.2011.328
35. Huertas D., Soler M., Moreto J., Villanueva A., Martinez A., Vidal A., Charlton M., Moffat D., Patel S., McDermott J., Owen J., Brotherton D., Krige D., Cuthill S., Esteller M., Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. Oncogene 2012 31 11 1408 1418 2-s2.0-84858333989 10.1038/onc.2011.335
36. Xiong S., Zheng Y., Jiang P., Liu R., Liu X., Chu Y., MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. International Journal of Biological Sciences 2011 7 6 805 814 2-s2.0-79960983743
37. LoPiccolo J., Granville C. A., Gills J. J., Dennis P. A., Targeting Akt in cancer therapy. Anti-Cancer Drugs 2007 18 8 861 874 2-s2.0-34547650639 10.1097/CAD.0b013e3280cc2c6f (Pubitemid 47220704)
38. Obenauer J. C., Cantley L. C., Yaffe M. B., Scansite 2.0: proteome-wide prediction of cell signalling interactions using short sequence motifs. Nucleic Acids Research 2003 31 13 3635 3641 2-s2.0-0042622251 10.1093/nar/gkg584 (Pubitemid 37442212)
39. Crul M., Rosing H., De Klerk G. J., Dubbelman R., Traiser M., Reichert S., Knebel N. G., Schellens J. H. M., Beijnen J. H., Ten Bokkel Huinink W. W., Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. European Journal of Cancer 2002 38 12 1615 1621 2-s2.0-0036345448 10.1016/S0959-8049(02)00127-2 (Pubitemid 34876501)
40. Kondapaka S. B., Singh S. S., Dasmahapatra G. P., Sausville E. A., Roy K. K., Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Molecular Cancer Therapeutics 2003 2 11 1093 1103 2-s2.0-2542547908
41. Nyåkern M., Cappellini A., Mantovani I., Martelli A. M., Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Molecular Cancer Therapeutics 2006 5 6 1559 1570 2-s2.0-33746046785 10.1158/1535-7163.MCT-06-0076 (Pubitemid 44070493)
42. Hideshima T., Catley L., Yasui H., Ishitsuka K., Raje N., Mitsiades C., Podar K., Munshi N. C., Chauhan D., Richardson P. G., Anderson K. C., Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006 107 10 4053 4062 2-s2.0-33646577479 10.1182/blood-2005-08-3434 (Pubitemid 43726814)
43. Momota H., Nerio E., Holland E. C., Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Research 2005 65 16 7429 7435 2-s2.0-23844457178 10.1158/0008-5472.CAN-05-1042 (Pubitemid 41161277)
44. Carón R. W., Yacoub A., Li M., Zhu X., Mitchell C., Hong Y., Hawkins W., Sasazuki T., Shirasawa S., Kozikowski A. P., Dennis P. A., Hagan M. P., Grant S., Dent P., Activated forms of H-RAS and K-RAS differentially regulate membrane association of P13K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Molecular Cancer Therapeutics 2005 4 2 257 270 2-s2.0-20044375047 (Pubitemid 40340205)
45. Ruiter G. A., Zerp S. F., Bartelink H., Van Blitterswijk W. J., Verheij M., Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Research 1999 59 10 2457 2463 2-s2.0-0033563010 (Pubitemid 29242297)
46. Vink S. R., Schellens J. H. M., Beijnen J. H., Sindermann H., Engel J., Dubbelman R., Moppi G., Hillebrand M. J. X., Bartelink H., Verheij M., Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiotherapy and Oncology 2006 80 2 207 213 2-s2.0-33748134734 10.1016/j.radonc.2006.07.032 (Pubitemid 44314020)
47. Leleu X., Jia X., Runnels J., Ngo H. T., Moreau A.-S., Farag M., Spencer J. A., Pitsillides C. M., Hatjiharissi E., Roccaro A., O'Sullivan G., McMillin D. W., Moreno D., Kiziltepe T., Carrasco R., Treon S. P., Hideshima T., Anderson K. C., Lin C. P., Ghobrial I. M., The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2007 110 13 4417 4426 2-s2.0-39149141606 10.1182/blood-2007-05-092098 (Pubitemid 351377808)
48. Yang L., Dan H. C., Sun M., Liu Q., Sun X.-M., Feldman R. I., Hamilton A. D., Polokoff M., Nicosia S. V., Herlyn M., Sebti S. M., Cheng J. Q., Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Research 2004 64 13 4394 4399 2-s2.0-3042743988 10.1158/0008-5472.CAN-04- 0343 (Pubitemid 38856907)
49. Marimpietri D., Brignole C., Nico B., Pastorino F., Pezzolo A., Piccardi F., Cilli M., Di Paolo D., Pagnan G., Longo L., Perri P., Ribatti D., Ponzoni M., Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clinical Cancer Research 2007 13 13 3977 3988 2-s2.0-34447124424 10.1158/1078-0432.CCR-06-2757 (Pubitemid 47037606)
50. Marimpietri D., Nico B., Vacca A., Mangieri D., Catarsi P., Ponzoni M., Ribatti D., Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. Oncogene 2005 24 45 6785 6795 2-s2.0-27144515334 10.1038/sj.onc.1208829 (Pubitemid 41487037)
51. Hjelmeland A. B., Lattimore K. P., Fee B. E., Shi Q., Wickman S., Keir S. T., Hjelmeland M. D., Batt D., Bigner D. D., Friedman H. S., Rich J. N., The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Molecular Cancer Therapeutics 2007 6 9 2449 2457 2-s2.0-34748821802 10.1158/1535-7163.MCT- 07-0155 (Pubitemid 47480410)
52. Rao R. D., Mladek A. C., Lamont J. D., Goble J. M., Erlichman C., James C. D., Sarkaria J. N., Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 2005 7 10 921 929 2-s2.0-33644877965 10.1593/neo.05361
53. Wang M. Y., Lu K. V., Zhu S., Dia E. Q., Vivanco I., Shackleford G. M., Cavenee W. K., Mellinghoff I. K., Cloughesy T. F., Sawyers C. L., Mischel P. S., Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Research 2006 66 16 7864 7869 2-s2.0-33748058820 10.1158/0008-5472.CAN-04-4392 (Pubitemid 44299148)
54. Buck E., Eyzaguirre A., Brown E., Petti F., McCormack S., Haley J. D., Iwata K. K., Gibson N. W., Griffin G., Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Molecular Cancer Therapeutics 2006 5 11 2676 2684 2-s2.0-33845227643 10.1158/1535-7163.MCT-06-0166 (Pubitemid 44848994)
55. Masiello D., Mohi M. G., McKnight N. C., Smith B., Neel B. G., Balk S. P., Bubley G. J., Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer. Cancer Biology and Therapy 2007 6 2 195 201 2-s2.0-34247370642 (Pubitemid 46641623)
56. Jimeno A., Kulesza P., Wheelhouse J., Chan A., Zhang X., Kincaid E., Chen R., Clark D. P., Forastiere A., Hidalgo M., Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. British Journal of Cancer 2007 96 6 952 959 2-s2.0-33947422073 10.1038/sj.bjc.6603656 (Pubitemid 46452288)
57. Costa L. J., Gemmill R. M., Drabkin H. A., Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells. Urology 2007 69 3 596 602 2-s2.0-33947266995 10.1016/j.urology.2007.01.053 (Pubitemid 46428416)
58. Gemmill R. M., Zhou M., Costa L., Korch C., Bukowski R. M., Drabkin H. A., Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma. British Journal of Cancer 2005 92 12 2266 2277 2-s2.0-22044438985 10.1038/sj.bjc.6602646 (Pubitemid 40966266)
59. Mohi M. G., Boulton C., Gu T.-L., Sternberg D. W., Neuberg D., Griffin J. D., Gilliland D. G., Neel B. G., Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proceedings of the National Academy of Sciences of the United States of America 2004 101 9 3130 3135 2-s2.0-1542327671 10.1073/pnas.0400063101 (Pubitemid 38327746)
60. Birle D. C., Hedley D. W., Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts. Molecular Cancer Therapeutics 2006 5 10 2494 2502 2-s2.0-33750452256 10.1158/1535-7163.MCT-05-0504 (Pubitemid 44650913)
61. Xie X., Ghadimi M. P. H., Young E. D., Belousov R., Zhu Q.-S., Liu J., Lopez G., Colombo C., Peng T., Reynoso D., Hornick J. L., Lazar A. J., Lev D., Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. Clinical Cancer Research 2011 17 18 5901 5912 2-s2.0-80052833534 10.1158/1078-0432.CCR-11-0660
62. Kumar A., Rajendran V., Sethumadhavan R., Purohit R., Relationship between a point mutation S97C in CK1 δ protein and its affect on ATP-binding affinity. Journal of Biomolecular Structure and Dynamics 2013 10.1080/07391102.2013.770373
63. Kumar A., Rajendran V., Sethumadhavan R., Purohit R., Computational investigation of cancer-associated molecular mechanism in Aurora A (S155R) mutation. Cell Biochemistry and Biophysics 2013 10.1007/s12013-013-9524-9
64. Balu K., Rajendran V., Sethumadhavan R., Purohit R., Investigation of binding phenomenon of NSP3 and p130Cas mutants and their effect on cell. Cell Biochemistry and Biophysics 2013 67 2 623 633 10.1007/s12013-013-9551-6
65. Rajendran V., Purohit R., Sethumadhavan R., In silico investigation of molecular mechanism of laminopathy caused by a point mutation (R482W) in lamin A/C protein. Amino Acids 2012 43 2 603 615 2-s2.0-80053579648 10.1007/s00726-011-1108-7
66. Purohit R., Sethumadhavan R., Structural basis for the resilience of Darunavir (TMC114) resistance major flap mutations of HIV-1 protease. Interdisciplinary Sciences, Computational Life Sciences 2009 1 4 320 328 2-s2.0-77956634216 10.1007/s12539-009-0043-8
67. Purohit R., Rajendran V., Sethumadhavan R., Relationship between mutation of serine residue at 315th position in M. tuberculosis catalase-peroxidase enzyme and Isoniazid susceptibility: An in silico analysis. Journal of Molecular Modeling 2011 17 4 869 877 2-s2.0-79958089433 10.1007/s00894-010-0785-6
68. Kumar A., Rajendran V., Sethumadhavan R., Purohit R., Insight into Nek2A activity regulation and its pharmacological prospects. Egyptian Journal of Medical Human Genetics 2013 14 3 213 219 10.1016/j.ejmhg.2012.10.006
69. Kumar A., Rajendran V., Sethumadhavan R., Shukla P., Tiwari S., Purohit R., Computational SNP analysis: current approaches and future prospects. Cell Biochemistry and Biophysics 2013 10.1007/s12013-013-9705-6
70. Kumar A., Rajendran V., Sethumadhavan R., Purohit R., In silico prediction of a disease-associated STIL mutant and its affect on the recruitment of centromere protein J (CENPJ). FEBS Open Bio 2012 2 285 293
71. Purohit R., Role of ELA region in auto-activation of mutant KIT receptor; a molecular dynamics simulation insight. Journal of Biomolecular Structure & Dynamics 2013 10.1080/07391102.2013.803264
72. Rajendran V., Sethumadhavan R., Drug resistance mechanism of PncA in Mycobacterium tuberculosis. Journal of Biomolecular Structure and Dynamics 2013 10.1080/07391102.2012.759885
73. Balu K., Purohit R., Mutational analysis of TYR gene and its structural consequences in OCA1A. Gene 2013 513 1 184 195
74. Wang K., Li P.-F., Foxo3a regulates apoptosis by negatively targeting miR-21. Journal of Biological Chemistry 2010 285 22 16958 16966 2-s2.0-77952760958 10.1074/jbc.M109.093005